A new study published in the journal Immunity reveals a mechanism that allows triple negative breast cancer (TNBC) to develop resistance to therapy. Researchers at Baylor College of Medicine showed ...

Gilead Sciences has cemented the role of its TROP2 drug Trodelvy in triple-negative breast cancer (TNBC) with a win in a phase 3 combination trial with MSD's PD-1 inhibitor Keytruda. ASCENT-04 ...

Neoadjuvant chemotherapy (NACT) use in triple-negative breast cancer (TNBC) increased from 19.1% to 56.4% between 2010 and 2021, with pathologic complete response (pCR) rates rising from 19.6% to ...

AstraZeneca’s first-in-class pan-AKT inhibitor Truqap was unable to improve overall survival (OS) in a phase 3 trial in triple-negative breast cancer (TNBC), denting the prospects of the new drug.

Besides Ascent-04, Gilead expects a readout by June from the phase 3 Ascent-03 trial pitting Trodelvy against chemo in first-line, PD-L1-negative metastatic TNBC. The Ascent-05 study is testing ...